Targeting Gli transcription activation by small molecule suppresses tumor growth

Oncogene

Volumn 33, Issue 16, 2014, Pages 2087-2097

  Bosco Clement G ^a   Zhang, F ^a,b   Chen, Z ^a,b   Zhou, H M ^b   Li, H ^a   Mikami, I ^a,c   Hirata, T ^a,c   Yagui Beltran, A ^a   Lui, N ^a   Do, H T ^a   Cheng, T ^a   Tseng, H H ^a   Choi, H ^a   Fang, L T ^a   Kim, I J ^a   Yue, D ^a,d   Wang, C ^d   Zheng, Q ^a,e   Fujii, N ^f   Mann, M ^g   Jablons, D M ^a   He, B ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TSINGHUA UNIVERSITY   (China)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; Gli; Hedgehog pathway; TAF9; targeted therapy

Indexed keywords

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HCT116 CELLS; HEDGEHOG PROTEINS; HEK293 CELLS; HT29 CELLS; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; NEOPLASMS; NIH 3T3 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SMALL MOLECULE LIBRARIES; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTOR TFIID; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899463037     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.164     Document Type: Article

References (52)

1. Varjosalo M, Taipale J. Hedgehog: Functions and mechanisms. Genes Dev 2008; 22: 2454-2472
2. Merchant AA, Matsui W. Targeting Hedgehog-A cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-3140
3. Kalderon D. Transducing the hedgehog signal. Cell 2000; 103: 371-374
4. Hooper JE, Scott MP. Communicating with Hedgehogs. Nat Rev Mol Cell Biol 2005; 6: 306-317
5. Huangfu D, Anderson KV. Signaling from Smo to Ci/Gli: Hedgehog pathways from Drosophila to vertebrates. Development 2006; 133: 3-14
6. Ruiz i Altaba A, Mas C, Stecca B. The Gli code: And information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007; 17: 438-447
7. Mullor JL, Dahmane N, Sun T, Ruiz i Altaba A. Wnt signals are targets and mediators of Gli function. Curr Biol 2001; 1: 769-773
8. Yang L, Xie G, Fan Q, Xie J. Activation of the Hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010; 29: 469-481
9. Scales SJ, De Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30: 303-312
10. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, et al. Medulloblastoma growth inhibition by Hedgehog pathway blockade. Science 2002; 297: 1559-1561
11. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422: 313-317
12. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004; 431: 707-712
13. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67: 2187-2196
14. Clement V, Sanchez P, De Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOGGLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17: 165-172
15. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361: 1173-1178
16. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-2511
17. Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC, et al. Discovery of a potent and orally active Hedgehog pathway antagonist (IPI-926). J Med Chem 2009; 52: 4400-4418
18. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326: 572-574
19. Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011; 71: 435-444
20. Low JA, De Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010; 28: 5321-5326
21. Dennler S, Andre' J, Alexaki I, Li A, Magnaldo T, ten Dijke P, et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007; 67: 6981-6986
22. Dennler S, Andre' J, Verrecchia F, Mauviel A. Cloning of the human Gli2 promoter: Transcriptional activation by Tgf-beta via Smad3/beta-catenin cooperation. J Biol Chem 2009; 284: 31523-31531
23. Guo X, Wang XF. Signaling cross-Talk between TGF-beta/BMP and other pathways. Cell Res 2009; 19: 71-88
24. Ji ZY, Mei FC, Xie J, Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007; 282: 14048-14055
25. Riobo NA, Haines GM, Emerson Jr CP. Protein kinase C-delta and mitogenactivated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling. Cancer Res 2006; 66: 839-845
26. Riobo NA, Lu K, Ai X, Haines GM, Emerson Jr CP. Phosphoinositide 3-kinase and Akt are essential for sonic hedgehog signaling. Proc Natl Acad Sci USA 2006; 103: 4505-4510
27. Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-Kronberger C, et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009; 69: 1284-1292
28. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, et al. Melanomas require HEDGEHOG-GLI signaling reaulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 2007; 104: 5895-5900
29. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 2006; 20: 3161-3173
30. Lauth M, Toftgård R. Non-canonical activation of GLI transcription factors. Cell Cycle 2007; 6: 2458-2463
31. Lauth M, Bergstrom A, Shimokawa T, Toftgård R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007; 104: 8455-8460
32. Yoon JW, Liu CZ, Yang JT, Swart R, Iannaccone P, Walterhouse D. GLI activates transcription through a herpes simplex viral protein 16-like activation domain. J Biol Chem 1998; 273: 3496-3501
33. Uesugi M, Verdine GL. The alpha-helical FXXPhiPhi motif in p53:TAF interaction and discrimination by MDM2. Proc Natl Acad Sci USA 1999; 96: 14801-14806
34. Choi Y, Asada S, Uesugi M. Divergent hTAFII31-binding motifs hidden in activation domains. J Biol Chem 2000; 275: 15912-15916
35. Rovnak J, Quackenbush SL. Walleye dermal sarcoma virus retroviral cyclin directly contacts TAF9. J Virol 2006; 80: 12041-12048
36. Falgout B, Ketner G. Characterization of adenovirus particles made by deletion mutants lacking the fiber gene. J Virol 1988; 62: 622-625
37. He B, Fujii N, You L, Xu Z, Jablons DM. Targeting Gli proteins in human cancer by small molecules US Patent No. 7714014, 2010
38. Ogryzko VV, Kotani T, Zhang X, Schiltz RL, Howard T, Yang XJ, et al. Histone-like TAFs within the PCAF histone acetylase complex. Cell 1998; 94: 35-44
39. Hoffmann A, Chiang CM, Oelgeschläger T, Xie X, Burley SK, Nakatani Y, et al. A histone octamer-like structure within TFIID. Nature 1996; 380: 356-359
40. Shao H, Revach M, Moshonov S, Tzuman Y, Gazit K, Albeck S, et al. Core promoter binding by histone-like TAF complexes. Mol Cell Biol 2005; 25: 206-219
41. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al. A paracrine requirement for hedgehog signaling in cancer. Nature 2008; 455: 406-410
42. Hosoya T, Arai MA, Koyano T, Kowithayakorn T, Ishibashi M. Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription. Chembiochem 2008; 9: 1082-1092
43. Hyman JM, Firestone AJ, Heine VM, Zhao Y, Ocasio CA, Han K, et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci USA 2009; 106: 14132-14137
44. Rifai Y, Arai M, Sadhu S, Ahmed F, Ishibashi M. New Hedgehog/GLI signaling inhibitors from Excoecaria agallocha. Bioorg Med Chem Lett 2011; 21: 718-722
45. Arai M, Tateno C, Koyano T, Kowithayakorn T, Kawabe S, Ishibashi M. New Hedgehog/GLI-signaling inhibitors from Adenium obesum. Org Biomol Chem 2011; 9: 1133-1139
46. Jung D, Choi Y, Uesugi M. Small organic molecules that modulate gene transcription. Drug Discov Today 2006; 11: 452-457
47. Shimogawa H, Kwon Y, Mao Q, Kawazoe Y, Choi Y, Asada S, et al. A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction. J Am Chem Soc 2004; 126: 3461-3471
48. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848
49. Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, et al. Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun 2004; 323: 229-234
50. Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, et al. EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene 2010; 29: 5969-5975
51. Raz D, Ray MR, Kim JY, He B, Taron M, Skrzypski M, et al. A multi-gene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008; 14: 5565-5570
52. Okamoto J, Kratz JR, Hirata T, Mikami I, Raz D, Segal M, et al. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients. Clin Lung Cancer 2011; 12: 237-244